Tiblio
Sign Up

IPHA

Innate Pharma
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$160.85M
P/E Ratio
—
EPS
$-0.61
Beta
1.22
52W High
$2.71
52W Low
$1.17
50-Day MA
$1.70
200-Day MA
$1.71
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Innate Pharma

Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$9.81M
Gross Profit (TTM)$-30.17M
EBITDA$-46.96M
Operating Margin-335.70%
Return on Equity-271.40%
Return on Assets-46.60%
Revenue/Share (TTM)$0.10
Book Value$-0.48
Price-to-Book30.69
Price-to-Sales (TTM)16.40
EV/Revenue35.25
EV/EBITDA-6.94
Quarterly Earnings Growth (YoY)-74.70%
Quarterly Revenue Growth (YoY)16.50%
Shares Outstanding$111.70M
Float$68.87M
% Insiders1.40%
% Institutions0.35%

Historical Volatility

HV 10-Day
59.46%
HV 20-Day
65.16%
HV 30-Day
64.52%
HV 60-Day
67.22%
HV Rank
—

Volatility is currently contracting

Analyst Ratings

Consensus ($6.67 target)
3
Buy

Latest News

Innate Pharma Q3 Earnings Call Highlights

Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the company outlined its third-quarter 2026 business update.

MarketBeat11/5/2026Neutral
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research10/8/2026Positive
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)

Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research10/5/2026Positive
Innate Pharma Q2 Earnings Call Highlights

Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and completed enrollment in the PACIFIC-9 phase III study of monalizumab.

MarketBeat9/17/2026Neutral
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the previously announced strategic partnership with Sobi is now effective following the expiration of applicable antitrust waiting periods and completion of other conditions. As announced on August 10, 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma. Transaction closing triggers the USD 75.

Business Wire9/16/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IPHA and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncMRKMerck & Company IncUNHUnitedHealth Group IncorporatedNVSNovartis AG ADRAZNAstraZeneca PLCTMOThermo Fisher Scientific IncAMGNAmgen IncGILDGilead Sciences IncABTAbbott LaboratoriesNVONovo Nordisk A/S
View all HEALTHCARE stocks →
Data last updated: 11/7/2026